Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has announcements × olaparib × Gastrointestinal × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 5 Breast 2 Genitourinary 1 Gastrointestinal 1 Classical hematology 1

Conditions

Pancreatic Neoplasms 1

Interventions

pembrolizumab 9 Fluorouracil 8 Oxaliplatin 6 Nivolumab 6 Leucovorin 6 Sorafenib 5 Ipilimumab 5 Cetuximab 5 Bevacizumab 5 Irinotecan 4 Cisplatin 4 Capecitabine 4 trifluridine tipiracil drug combination 3 trastuzumab deruxtecan 3 cabozantinib 3 zolbetuximab 2 selpercatinib 2 lenvatinib 2 encorafenib 2 durvalumab 2 Paclitaxel 2 HMPL-013 2 Gemcitabine 2 Docetaxel 2 zenocutuzumab 1 zanidatamab 1 tucatinib 1 tremelimumab 1 trametinib 1 toripalimab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02184195 2023-09-13

POLO

AstraZeneca

Phase 3 Completed

154 enrolled 20 charts 1 FDA

Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡